MYGNHealthcare · Diagnostics & ResearchThe 9 Wall Street analysts covering Myriad Genetics, Inc. hold a median 12-month price target of $4.6 — -23.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Myriad Genetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MYGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −23.5% from it.
Of the 20 most recent actions, 2 moved their price target up and 7 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | TD Cowen | Maintains | Hold | $4.00 → $4.50 |
| 2 Oct 2026 | Craig-Hallum | Maintains | Buy | $4.00 → $8.00 |
| 2 Oct 2026 | Craig-Hallum | Maintains | Buy | — |
| 9 Sept 2026 | UBS | Maintains | Neutral | $6.00 → $3.60 |
| 9 Sept 2026 | UBS | Maintains | Neutral | — |
| 1 Sept 2026 | Piper Sandler | Downgrade | Underweight | — |
| 1 Sept 2026 | Piper Sandler | Downgrade | Underweight | $5.45 → $2.00 |
| 18 Aug 2026 | Stephens & Co. | Maintains | Equal-Weight | $5.00 → $3.00 |
| 18 Aug 2026 | Stephens & Co. | Maintains | Equal-Weight | — |
| 3 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $5.50 → $3.00 |
| 3 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 31 July 2026 | TD Cowen | Maintains | Hold | $6.00 → $4.00 |
| 31 July 2026 | TD Cowen | Maintains | Hold | — |
| 6 May 2026 | TD Cowen | Maintains | Hold | — |
| 6 May 2026 | TD Cowen | Maintains | Hold | $7.00 → $6.00 |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | $6.00 → $5.50 |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 24 Feb 2026 | UBS | Maintains | Neutral | — |
| 24 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MYGN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Myriad Genetics, Inc. returned −7.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 75% of US stocks
Cheaper than 45% of US stocks
Cheaper than 89% of US stocks
Higher than 16% of US stocks
Higher than 27% of US stocks
Higher than 80% of US stocks
Higher than 21% of US stocks
Higher than 17% of US stocks
Higher than 27% of US stocks
Higher than 28% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Myriad Genetics, Inc. has a market value of $574.9M and an enterprise value of $673.0M.
Revenue in the twelve months to 30 June 2026: $806.6M. The latest quarter shrank 10.5% year on year.
Net income over the same four quarters: −$112.6M, a −14.0% net margin.
Diluted earnings per share, trailing twelve months: $−1.19.
Free cash flow in the twelve months to 30 June 2026: −$14.2M, after $21.9M of capital spending.
Trailing P/E: −1.5×; forward P/E: −10.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Myriad Genetics, Inc. employs 2,700 people — $299K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Myriad Genetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Myriad Genetics reported a third-quarter loss of $0.11 per share, compared with the Zacks consensus estimate of a $0.17 loss. The company reported break-even earnings per share a year earlier.
Why it matters — The reported loss was narrower than the consensus estimate, providing MYGN watchers an update on quarterly earnings performance.
Myriad Genetics reported third-quarter revenue of $202.7 million, down 1% year over year, as growth in cancer and mental health testing was offset by lower prenatal revenue. The company raised its full-year revenue outlook and said early efforts to address reimbursement denials improved revenue per test.
Why it matters — MYGN watchers may note the mixed business performance alongside a higher full-year revenue outlook and improving revenue per test.
Myriad Genetics reported third-quarter 2026 revenue of $202.7 million, up 6% sequentially and down 1% year over year. Higher Cancer Care Continuum product mix and payer engagement and revenue cycle initiatives lifted average revenue per test, partly offset by lower test volumes.
Why it matters — Investors following MYGN may note the revenue trends and the mix of per-test gains and volume declines in the quarter.
Myriad Genetics announced that its management will participate in three upcoming healthcare conferences. The excerpt identifies a UBS Global Healthcare Conference fireside chat on Nov. 10, 2026, at 1:15 p.m. ET.
Why it matters — The conference appearances give MYGN watchers a scheduled opportunity to hear from company management.
Myriad Genetics announced new MONSTAR-SCREEN-3 data on its whole-genome sequencing-based Precise MRD platform for ultra-sensitive molecular residual disease detection in resectable colorectal and pancreatic cancers. The findings are slated for presentation at the ESMO Congress 2026.
Why it matters — The study update highlights development of Myriad’s MRD testing platform in cancer types where testing after surgery may inform monitoring and treatment decisions.
The 9 Wall Street analysts covering Myriad Genetics, Inc. have a median 12-month price target of $4.6, with estimates ranging from $2.5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Myriad Genetics, Inc., 1 rate it a Buy, 6 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Myriad Genetics, Inc. 58 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Myriad Genetics, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies -23.5% from the last close, and Ticker Nerd's factor model ranks Myriad Genetics, Inc. 58 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Myriad Genetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MYGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $8 over the next 12 months.
Myriad Genetics, Inc. returned -7.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops and commercializes genetic tests to support disease risk assessment, diagnosis, treatment selection, and patient management.
The most recent item we track (Zacks Investment Research, 5 Nov 2026): "Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates". Myriad Genetics reported a third-quarter loss of $0.11 per share, compared with the Zacks consensus estimate of a $0.17 loss. The company reported break-even earnings per share a year earlier.
Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops and commercializes genetic tests to support disease risk assessment, diagnosis, treatment selection, and patient management. Its current portfolio focuses on oncology, women’s health, and pharmacogenomics, serving healthcare providers, patients, laboratories, and pharmaceutical partners. Key offerings include hereditary cancer testing through MyRisk, germline BRCA testing through BRACAnalysis CDx, and tumor profiling through MyChoice CDx, which helps identify biomarkers associated with treatment response in certain cancers. The company also provides pharmacogenomic testing designed to help clinicians evaluate how patients may respond to selected medications. Myriad’s services combine laboratory testing, genomic analysis, clinical interpretation, and reporting, connecting molecular information with medical decision-making. Headquartered in Salt Lake City, Utah, Myriad Genetics, Inc. occupies a specialized role in the healthcare market by translating genetic and molecular data into clinically actionable insights across cancer care, reproductive health, and medication management.
CEO Mr. Samraat S. Raha · 2,700 employees · United States · https://www.myriad.com
